Overbought Stocks
MANE appears in our Overbought Stocks screen, meaning it has experienced strong recent gains and may be trading at extended levels that could lead to short-term consolidation or pullback.
VERADERMICS INC (MANE) Stock Price & Overview
NYSE:MANE • US9229671048
Current stock price
106.55 USD
+3.45 (+3.35%)
At close:
106.55 USD
0 (0%)
After Hours:
The current stock price of MANE is 106.55 USD. Today MANE is up by 3.35%. In the past month the price increased by 68.73%.
MANE Key Statistics
1-Month Range53.68 - 110.12
Current MANE stock price positioned within its 1-month range.
- Market Cap
- 3.979B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.38
- Dividend Yield
- N/A
MANE Stock Performance
Today
+3.35%
1 Week
+51.54%
1 Month
+68.73%
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
MANE Stock Chart
MANE Stock Screens
MANE currently appears in the following ChartMill screener lists.
MANE Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to MANE.
Chartmill TA Rating
Chartmill Setup Rating
MANE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MANE. No worries on liquidiy or solvency for MANE as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MANE Earnings
Next Earnings DateN/A
Last Earnings DateN/A
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
MANE Forecast & Estimates
10 analysts have analysed MANE and the average price target is 79.9 USD. This implies a price decrease of -25.01% is expected in the next year compared to the current price of 106.55.
Analysts
Analysts88
Price Target79.9 (-25.01%)
EPS Next Y93.8%
Revenue Next YearN/A
MANE Financial Highlights
Over the last trailing twelve months MANE reported a non-GAAP Earnings per Share(EPS) of -2.38. The EPS decreased by -205.36% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-83.37M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.63% | ||
| ROE | -58.11% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-335.59%
Sales Q2Q%N/A
EPS 1Y (TTM)-205.36%
Revenue 1Y (TTM)N/A
MANE Ownership
Ownership
Inst Owners40.09%
Shares37.34M
Float34.17M
Ins Owners3.39%
Short Float %5.24%
Short Ratio3.98
MANE Industry Overview
MANE operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
65/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
17/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
62%
Outperformed 62% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 4.4%
- Average ROE
- 50.6%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.5%
- Average P/E
- 25.0
- Average Fwd P/E
- 19.7
- Average Debt/Equity
- 1.2
MANE Latest News, Press Relases and Analysis
MANE Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 24.34 | 825.773B | ||
| JNJ | JOHNSON & JOHNSON | 17.92 | 548.657B | ||
| MRK | MERCK & CO. INC. | 21.79 | 271.761B | ||
| PFE | PFIZER INC | 8.79 | 150.628B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.1 | 118.952B | ||
| ZTS | ZOETIS INC | 16.09 | 49.054B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.58 | 28.582B | ||
| VTRS | VIATRIS INC | 6 | 17.257B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 20.72 | 11.061B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.463B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.11B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.955B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.86 | 4.959B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MANE
Company Profile
Veradermics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New Haven, Connecticut and currently employs 19 full-time employees. The company went IPO on 2026-02-04. Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The firm is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The firm is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The firm is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Company Info
IPO: 2026-02-04
VERADERMICS INC
470 James Street
New Haven CONNECTICUT US
Employees: 19
Phone: 18009279800
VERADERMICS INC / MANE FAQ
What does MANE do?
Veradermics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in New Haven, Connecticut and currently employs 19 full-time employees. The company went IPO on 2026-02-04. Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The firm is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The firm is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The firm is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
What is the current price of MANE stock?
The current stock price of MANE is 106.55 USD. The price increased by 3.35% in the last trading session.
What is the dividend status of VERADERMICS INC?
MANE does not pay a dividend.
What is the ChartMill technical and fundamental rating of MANE stock?
MANE has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Should I buy MANE stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MANE.
What is VERADERMICS INC worth?
VERADERMICS INC (MANE) has a market capitalization of 3.98B USD. This makes MANE a Mid Cap stock.